KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cash from Investing Activities for 6 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 100.45% year-over-year to -$1.2 million, compared with a TTM value of -$16.9 million through Dec 2025, down 106.49%, and an annual FY2025 reading of -$16.9 million, down 106.49% over the prior year.
  • Cash from Investing Activities was -$1.2 million for Q4 2025 at Recursion Pharmaceuticals, up from -$2.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $275.5 million in Q4 2024 and bottomed at -$193.9 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is $7.7 million, with a median of -$4.4 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 15828.21% in 2021, then skyrocketed 11171.38% in 2024.
  • Year by year, Cash from Investing Activities stood at -$52.2 million in 2021, then skyrocketed by 84.73% to -$8.0 million in 2022, then skyrocketed by 68.82% to -$2.5 million in 2023, then surged by 11171.38% to $275.5 million in 2024, then plummeted by 100.45% to -$1.2 million in 2025.
  • Business Quant data shows Cash from Investing Activities for RXRX at -$1.2 million in Q4 2025, -$2.5 million in Q3 2025, and -$5.8 million in Q2 2025.